[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"wedge-resection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:wedge-resection":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,45,66,89,119],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100641875","pre-incisional-infiltration-with-ropivacaine-plus-diprospan-for-relieving-postoperative-pain-after-thoracoscopic-surgery-100641875",false,"NCT07626489","Pre-incisional Infiltration With Ropivacaine Plus Diprospan for Relieving Postoperative Pain After Thoracoscopic Surgery","The Efficacy and Safety of Pre-incisional Infiltration With Ropivacaine Plus Diprospan in Patients Undergoing Video-assisted Thoracoscopic: a Multi-center Randomized Controlled Trial.","Inclusion Criteria:\n\n1. Patients scheduled for elective Video-assisted thoracoscopic surgery for wedge resection, segmentectomy and lobectomy of the lungs under general anesthesia;\n2. 8 to 64 years old\n3. American Society of Anesthesiologists (ASA) physical status of I-III\n4. Patients must be able to understand the nature and potential personal consequences of the clinical trial and cooperate with follow-up investigations\n5. signing of the informed consent form.\n\nExclusion Criteria:\n\n1. History of allergies to experimental drugs such as opioids or steroids;\n2. Alcohol abuse; Long term use of opioid drugs (exceeding 2 weeks or 3 days per week for more than 1 month); Suspected use of sedatives and analgesics; Use analgesic drugs within 24 hours before surgery; Patients undergoing steroid therapy;\n3. Serious neurological disorders, severe liver and kidney dysfunction, heart failure, etc;\n4. Unable to use pain assessment scale;\n5. Pregnant or lactating patients.","ALL","18 Years","64 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"NA","Video-assisted thoracoscopic surgery (VATS) is less invasive compared to traditional thoracotomy, but it is still reported that the incidence of acute pain following VATS exceeds 80%. Inadequate postoperative analgesia may trigger a series of adverse physiological stress responses, increase the occurrence of postoperative complications, and affect the rehabilitation process. If acute pain is not managed promptly and sufficiently, nearly one-quarter of patients may develop chronic pain, impacting normal life and sleep quality after discharge. Acute pain after VATS is mainly caused by the release of inflammatory mediators after soft tissue injury at the surgical site, which activates peripheral pain receptors and leads to abnormal action potentials transmitted along A δ and C fibers. Inflammatory mediators released from the soft tissues around incisions not only significantly alters the chemical microenvironment at the peripheral terminals of nociceptors, directly inducing pain, but also sensitizes afferent fibers, contributing to peripheral sensitization.\n\nIncisional infiltration is the simplest, safest, and most effective anesthesia method for preventing incision pain after VATS, but even using long-acting local anesthetics, the effectiveness of postoperative analgesia can only last for a relatively short period of time. To improve the efficiency of local incision infiltration in postoperative analgesia, at least two issues need to be addressed: prolonging the duration of analgesia and reducing inflammation of nerve surrounding tissues. Numerous studies have shown that glucocorticoids not only can achieve anti-inflammatory and analgesic effects by inhibiting inflammatory cytokines and inflammatory responses but also can prolong the duration of action of local anesthetics. Preemptive incisional infiltration using local anesthetics with corticosteroids which have potent local anti-inflammatory properties may play a key role in preventing or reducing postoperative pain. The objective of this trial is to determine whether preemptive incisional infiltration with ropivacaine plus diprospan is superior to ropivacaine alone in relieving postoperative pain for adults undergoing VATS. The investigators also compare the effects of the two intervention measures on postoperative pain management, patient safety, and recovery quality.",[27,28,29,30,31],"Video-assisted Thoracoscopic Surgery (VATS)","Wedge Resection","Segmentectomy","Lobectomy","Infiltration Anesthesia","RECRUITING","2026-06-16",{"date":35,"type":36},"2026-06-17","ACTUAL",{"date":38,"type":21},"2026-05-30",{"date":40,"type":21},"2028-05-30",{"name":42,"class":43},"Beijing Tiantan Hospital","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":44},"100642912","pre-incisional-infiltration-with-ropivacaine-plus-triamcinolone-for-relieving-postoperative-pain-after-thoracoscopic-surgery-100642912","NCT07603921","Pre-incisional Infiltration With Ropivacaine Plus Triamcinolone for Relieving Postoperative Pain After Thoracoscopic Surgery","The Efficacy and Safety of Pre-incisional Infiltration With Ropivacaine Plus Triamcinolone in Patients Undergoing Video-assisted Thoracoscopic: a Multi-center Randomized Controlled Trial.","Inclusion Criteria:\n\n1. Patients scheduled for elective thoracoscopic wedge resection, segmentectomy, and lobectomy under general anesthesia;\n2. Ages 18 to 64 years old\n3. American Society of Anesthesiologists (ASA) physical status of I-III\n4. Patients must be able to understand nature and potential personal consequences of the clinical trial and cooperation with follow-up investigations\n5. signing of the informed consent form.\n\nExclusion Criteria:\n\n1. History of allergies to experimental drugs such as opioids or steroids;\n2. Alcohol abuse; Long term use of opioid drugs (exceeding 2 weeks or 3 days per week for more than 1 month); Suspected use of sedatives and analgesics; Use analgesic drugs within 24 hours before surgery; Patients undergoing steroid therapy;\n3. Serious neurological disorders, severe liver and kidney dysfunction, heart failure, etc;\n4. Unable to use pain assessment scale;\n5. Pregnant or lactating patients.",{"count":20,"type":21},[24],"Video-assisted thoracoscopic surgery (VATS) is less invasive compared to traditional thoracotomy, but it is still reported that the incidence of acute pain following VATS exceeds 80%. Inadequate postoperative analgesia may trigger a series of adverse physiological stress responses, increase the occurrence of postoperative complications, and affect the rehabilitation process. If acute pain is not managed promptly and sufficiently, nearly one-quarter of patients may develop chronic pain, impacting normal life and sleep quality after discharge. Acute pain after VATS is mainly caused by the release of inflammatory mediators after soft tissue injury at the surgical site, which activates peripheral pain receptors and leads to abnormal action potentials transmitted along A δ and C fibers. Inflammatory mediators released from the soft tissues around incisions not only significantly alters the chemical microenvironment at the peripheral terminals of nociceptors, directly inducing pain, but also sensitizes afferent fibers, contributing to peripheral sensitization. Incisional infiltration is the simplest, safest, and most effective anesthesia method for preventing incision pain after laparoscopic surgery but even using long-acting local anesthetics, the effectiveness of postoperative analgesia can only last for a relatively short period of time. To improve the efficiency of local incision infiltration in postoperative analgesia, at least two issues need to be addressed: prolonging the duration of analgesia and reducing inflammation of nerve surrounding tissues.\n\nNumerous studies have shown that glucocorticoids not only can achieve anti-inflammatory and analgesic effects by inhibiting inflammatory cytokines and inflammatory responses but also can prolong the duration of action of local anesthetics. The investigators conducted a multicenter, prospective, randomized controlled clinical study to explore whether preemptive incisional infiltration with ropivacaine plus triamcinolone is superior to ropivacaine alone in relieving postoperative pain for adults undergoing VATS. The investigators also compare the effects of the two intervention measures on postoperative pain management, patient safety, and recovery quality.",[27,28,29,56,57,58],"Lobectomy of the Lungs","Incisional Infiltration","Triamcinolone","2026-06-15",{"date":33,"type":36},{"date":62,"type":36},"2026-06-01",{"date":64,"type":21},"2028-03-31",{"name":42,"class":43},{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":73,"targetDuration":4,"studyType":22,"phases":75,"briefSummary":76,"conditions":77,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":86,"leadSponsor":88,"locationsCount":4},"100642646","the-efficacy-and-safety-of-loxoprofen-sodium-patch-in-relieving-postoperative-pain-after-thoracoscopic-surgery-100642646","NCT07591220","The Efficacy and Safety of Loxoprofen Sodium Patch in Relieving Postoperative Pain After Thoracoscopic Surgery","The Efficacy and Safety of Incisional Preemptive Analgesia Using Loxoprofen Sodium Patch in Patients Undergoing Thoracoscopic Surgery: a Multi-center Randomized Controlled Trial.","Inclusion Criteria:\n\n1. Patients scheduled for elective Video-assisted thoracoscopic surgery for wedge resection, segmentectomy and lobectomy of the lungs under general anesthesia;\n2. 8 to 64 years old;\n3. American Society of Anesthesiologists (ASA) physical status of I-III;\n4. Patients must be able to understand the nature and potential personal consequences of the clinical trial and cooperate with follow-up investigations\n5. signing of the informed consent form.\n\nExclusion Criteria:\n\n1. History of chronic pain syndrome of any cause and mental illness;\n2. Excessive alcohol or drug abuse, chronic opioid use (more than 2 weeks or 3 days per week for more than 1 month), use of drugs with confirmed or suspected sedative or analgesic effects, or use of any painkiller within 24 h before surgery;\n3. History of hypertension (Grade 3, extremely high risk);\n4. Pregnancy or breastfeeding;\n5. Extreme body mass index (BMI) (\\\u003C 15 or \\> 35);\n6. Participation in another interventional trial that interferes with the intervention or outcome of this trial;\n7. Digestive system diseases (such as peptic ulcers, gastric bleeding);\n8. Patients with coronary artery disease;\n9. Patients with renal impairment (serum creatinine \\> 176 µmol\u002FL) and abnormal liver function(alanine aminotransferase (ALT) and\u002For aspartate aminotransferase (AST) \\> 2× the upper limit of normal (ULN) or total bilirubin (TBIL) ≥ 1.5×ULN);\n10. Subjects with coagulation dysfunction (prothrombin time or activated partial thromboplastin time is higher than the normal threshold) or patients who are taking oral anticoagulants for other medical reasons and have not stopped it before surgery, such as warfarin or new anticoagulants rivaroxaban or dabigatran;\n11. Patients with a history of allergy to anyone of the study drugs;",{"count":74,"type":21},156,[24],"Video-assisted thoracoscopic surgery (VATS) is less invasive compared to traditional thoracotomy, but it is still reported that the incidence of acute pain following VATS exceeds 80%. Inadequate postoperative analgesia may trigger a series of adverse physiological stress responses, increase the occurrence of postoperative complications, and affect the rehabilitation process. If acute pain is not managed promptly and sufficiently, nearly one-quarter of patients may develop chronic pain, impacting normal life and sleep quality after discharge. Acute pain after VATS is mainly caused by the release of inflammatory mediators after soft tissue injury at the surgical site, which activates peripheral pain receptors and leads to abnormal action potentials transmitted along A δ and C fibers. Inflammatory mediators released from the soft tissues around incisions not only significantly alters the chemical microenvironment at the peripheral terminals of nociceptors, directly inducing pain, but also sensitizes afferent fibers, contributing to peripheral sensitization. Therefore, drugs with potent local anti-inflammatory properties such as Loxoprofen Sodium may play a key role in preventing or reducing postoperative pain. The investigators conducted a multicenter, prospective, randomized controlled clinical study to explore the use of Loxoprofen Sodium Patch for preoperative local incision analgesia in VATS patients. The investigators aim to observe whether this method can effectively alleviate postoperative incision pain, reduce the dosage of postoperative analgesics and the side effects caused using postoperative analgesics, improve patient satisfaction, and provide new ideas for postoperative analgesia in VATS patients, promoting rapid recovery after VATS.",[27,78,79,80,28,29,30],"Loxoprofen Sodium Patch","Local Incision","Postoperative Pain","NOT_YET_RECRUITING","2026-06-07",{"date":84,"type":36},"2026-06-10",{"date":62,"type":21},{"date":87,"type":21},"2028-04-30",{"name":42,"class":43},{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":16,"minAge":96,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":22,"phases":99,"briefSummary":100,"conditions":101,"keywords":107,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":44},"100555754","auricular-acupressure-in-prehabilitation-100555754","NCT06516198","Auricular Acupressure in Prehabilitation","A Pilot Study of the Utility of Auricular Acupressure in Enhancing Prehabilitation Benefits in Candidates for Thoracic Surgery.","Inclusion Criteria\n\n* Being considered for major lung surgery\n* Surgery is not scheduled for at least 2 weeks\n* Age ≥ 50 years\n* Able to understand English at a 4th grade level\n* No known contraindications to prehabilitation (strength, endurance, balance exercises)\n* Able to provide informed consent for participation\n* Has an adult care partner who will be available and capable of placing seeds\n* Has access to smart phone for communication and image sharing\n* Underwent frailty screening (given any score)\n* Able to perform spirometry testing in clinic\n\nExclusion Criteria:\n\n* Allergy to Vaccaria seeds\n* Medical condition affecting either ear preventing use of auricular acupressure such as eczema, frostbite, sunburn","50 Years",{"count":98,"type":21},40,[24],"Complementary medicine is recognized for its ability to enhance appetite, increase energy, reduce anxiety, decrease pain, and improve sleep, among many other benefits. Acupuncture is among the most frequent types of complementary medicine practiced in the US, and Medicare currently includes back pain as a reimbursable indication for this therapy. Acupuncture-related therapies may enhance efforts at prehabilitation in candidates for major lung resection.",[102,103,104,105,28,29,30,106],"Frailty","Thoracic","Prehabilitation","Lung Surgery","Pneumonectomy; Status",[108,109],"accupressure","vaccaria seeds","2025-12-02",{"date":112,"type":36},"2025-12-09",{"date":114,"type":36},"2025-07-21",{"date":116,"type":21},"2027-06-20",{"name":118,"class":43},"University of Chicago",{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":126,"enrollmentInfo":127,"targetDuration":4,"studyType":22,"phases":129,"briefSummary":131,"conditions":132,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":44},"100523934","phase-3-wedge-resection-for-ground-glass-opacity-featured-lung-cancer-ectop-1020-100523934","NCT06102161","Wedge Resection for Ground-glass Opacity-featured Lung Cancer (ECTOP-1020)","Wedge Resection for Ground-glass Opacity-featured Lung Cancer With Size Less Than 2cm and Consolidation-to-tumor Ratio Between 0.25 to 0.5: a Single-arm, Multi-center, Prospective, Confirmatory Phase III Trial","Inclusion Criteria:\n\n1. Patients who sign the informed consent form and are willing to complete the study according to the plan;\n2. Aged from 18 to 80 years old;\n3. ECOG equals 0 or 1;\n4. Not receiving lung cancer surgery before;\n5. Intraoperative or postoperative pathologic diagnosis of lung adenocarcinoma;\n6. Single lung nodules with ground-glass dominant or pure ground-glass on CT, or multiple lung nodules with the major lesion being the aforementioned nodules;\n7. The nodule has a consolidation-to-tumor ratio (CTR) between 0.25 and 0.5 (including 0.25 and 0.5), and the nodule size is less than or equal to 2 cm;\n8. peripheral type of nodes, namely, nodes in the outer 1\u002F3 of the lung field.\n9. cT1N0M0 tumors;\n10. Complete tumor resection by wedge resection as assessed by the surgeon;\n11. Not receiving chemotherapy or radiotherapy before.\n\nExclusion Criteria:\n\n1. Postoperative pathologic diagnosis of adenocarcinoma in situ or minimally invasive adenocarcinoma.\n2. CTR is not between 0.25-0.5 or nodule size greater than 2 cm;\n3. Cannot be completely resected by wedge resection;\n4. Invasive lung adenocarcinoma or lung malignancy other than lung adenocarcinoma diagnosed cytologically or pathologically;\n5. Receiving lung cancer surgery before;\n6. Receiving radiotherapy or chemotherapy.","80 Years",{"count":128,"type":21},286,[130],"PHASE3","This is a clinical trial from the Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1020. The goal of this clinical trial is to confirm the therapeutic effect of Wedge resection for ground-glass opacity-featured lung cancer with a size less than 2cm and a consolidation-to-tumor ratio between 0.25 to 0.5.",[133,28,134],"Lung Cancer","Ground-glass Opacity","2023-10-25",{"date":137,"type":36},"2023-10-26",{"date":139,"type":21},"2023-11",{"date":141,"type":21},"2030-11",{"name":143,"class":43},"Fudan University"]